INDOCO REMEDIES LIMITED
Location
Maharashtra
Founded
1947-08-23
Website
Risk Signals
87 news mentions monitored
Industry Context
This company is tracked across risk categories, including those related to its sector (e.g., Medicinal Chemicals and Botanical Products, Pharmaceutical Preparations), including supply chain integrity, ESG practices, labor disputes, and regulatory compliance.
Filter risk signals by topic
Select a theme below to explore the company’s news mentions in specific risk areas.
Recent Articles about INDOCO REMEDIES LIMITED
Live alerts from global media, monitored by Business Radar
2025-06-30 (marketsmojo.com)
Why is Indoco Remedies falling/rising?
As of 30-Jun, Indoco Remedies Ltd's stock price has risen to Rs 320.50, reflecting a short-term gain of 5.08%. Despite recent performance improvements, the company faces significant long-term challenges, including a declining operating profit and consistent underperformance against benchmarks, raising concerns about its future stability.
Read more
2025-05-22 (cnbctv18.com)
Indoco Remedies Q4 Results: Shares fall 7% as company reports loss, revenue drops 12% - CNBC TV18
Following the earnings announcement, shares of Indoco Remedies saw sharp fall. The stock fell over 12% from its day's high of ₹273.75 to hit a low of ₹240.25. As of 3:13 PM, the stock was trading at ₹242.40 on the BSE, down 7% for the day.
Read more
2024-01-24 (ndtvprofit.com)
Indoco Remedies Q3 Results Review - Another Quarter Of Weak Margins: Prabhudas Lilladher
Indoco Remedies Ltd.'s cut our FY25/FY26 earning per share by ~10%/4% to factor in low margins and lower sales across regulated markets. We downgrade stock from Buy to 'Accumulate' given weak earnings visibility, muted domestic formulation sales. Our numbers do factor in margin recovery with reduction in remediation cost from FY25. Indoco Remedies Q3 FY24 Ebitda was sharply below our estimates led by continued higher remediation cost and lower regulated market sales.
Read more